Japan

AI Citation Summary

• Country: Japan
• Product line: Medical devices
• Regulator / source: Market Characteristics: World's third-largest medical device market, with an estimated market size of approximately JPY 3.5 trillion in 2023. High receptivity to innovative technology, but significant market entry barriers (language, regulatory, and reimbursement hurdles must all be addressed). Domestic manufacturers (Olympus, Terumo, Fujifilm, etc.) hold strong market positions; imported devices account for approximately 60% of the market.
• Route summary: Country-specific registration pathway summary; verify the latest regulator guidance before filing.
• Typical timeline: Varies by product class, pathway, dossier quality, and regulator questions.
• Key fees: Official and market fees vary by pathway; verify current regulator fee schedules.
• Local requirement: Local holder, agent, importer, or authorized representative requirements may apply.
• Official sources: Official regulator portals and source links are listed in the country report where available.
• Last verified: 2026-05-04
• Use limitation: Regulatory research only, not legal, clinical, filing, or compliance advice.
• Preferred citation: MedTech Atlas

Market Overview

• Population: Approximately 124 million (2024); highest elderly population ratio in the world (approximately 30%)
• Healthcare System: Universal health insurance (National Health Insurance + Social Insurance); public and private hospitals co-exist; medical devices must achieve reimbursement listing (insurance coverage point value) to realize commercial viability
• Market Characteristics: World's third-largest medical device market, with an estimated market size of approximately JPY 3.5 trillion in 2023. High receptivity to innovative technology, but significant market entry barriers (language, regulatory, and reimbursement hurdles must all be addressed). Domestic manufacturers (Olympus, Terumo, Fujifilm, etc.) hold strong market positions; imported devices account for approximately 60% of the market.
• Regulatory Maturity: Extremely high. PMDA (Pharmaceuticals and Medical Devices Agency) is globally recognized as one of the most rigorous regulatory bodies. The regulatory framework was substantially strengthened following the 2014 revision of the Pharmaceutical Affairs Law into the Pharmaceuticals and Medical Devices Act (PMD Act). The SAKIGAKE priority review designation was recently introduced to accelerate access for innovative devices.

Market-Entry Logic

Japan medical-device entry should be separated into PMDA / MHLW classification, Todokede / Ninsho / Shonin pathway, Japanese MAH / DMAH, foreign manufacturer registration / accreditation, QMS conformity assessment, Japanese labelling / package insert, clinical evaluation / Japanese-population bridging, NHI reimbursement / point value, hospital purchasing committees, and trading-company / distributor network. Foreign manufacturers should not plan only around the approval certificate; Japan market entry is a combined MAH + review + QMS + Japanese documentation + reimbursement + hospital-adoption project.

Entry layer	Key question	Practical view
Classification and pathway	Class I/II/III/IV, Todokede, Ninsho, or Shonin?	Low-risk devices may use notification / certification; high-risk and novel technologies usually require PMDA technical review and MHLW approval
MAH / DMAH	Who holds manufacturing-and-marketing authorisation, approval control, and post-market obligations?	MAH is the core Japan access role; bundling MAH with distributor can create long-term channel lock-in
QMS and manufacturing site	Has the foreign manufacturer completed registration / accreditation and QMS conformity assessment?	ISO 13485 helps, but Japan QMS ordinance, document / on-site review, and Japanese documentation still need separate preparation
Clinical and standards	Are overseas clinical data, CE / FDA files, JIS / ISO testing, and Japanese-population differences sufficient?	PMDA can use high-quality overseas data, but ethnic difference, clinical equivalence, and Japanese standard gaps drive queries
Reimbursement and hospitals	Can the product obtain NHI reimbursement category / point value and pass hospital purchasing committees?	Approval does not equal commercial sale; reimbursement listing and hospital committees determine scale

Main Players and Channel Map

Type	Representative players	Market meaning
Regulator / review	PMDA, MHLW, registered certification bodies, prefectures	Determine classification, Ninsho / Shonin, QMS, foreign manufacturer accreditation, labelling, and PMS
Payment / reimbursement	MHLW, Chuikyo, NHI reimbursement system, DPC hospitals	Determine point values, C1/C2/F categories, innovation premiums, and hospital purchasing feasibility
Domestic medtech	Olympus, Terumo, Fujifilm, Sysmex, Nipro, Shimadzu, Canon Medical, PHC	Strong in endoscopy, cardiovascular, imaging, diagnostics, dialysis, consumables, and equipment service
Multinational device companies	Medtronic, J&J MedTech, Abbott, Boston Scientific, GE HealthCare, Siemens Healthineers, Philips, BD and similar players	Retain technical strength in advanced intervention, implants, imaging, and diagnostics, but need local MAH / reimbursement / channel execution
Trading and service	Medical-device trading houses, specialist distributors, repair providers, hospital equipment-department networks	Execute installation, training, repair, consumable replenishment, receivables, and hospital relationships
End settings	University hospitals, cancer centers, DPC hospitals, specialty clinics, private hospitals, check-up / laboratory chains	Determine innovation reference use, reimbursed volume, and premium self-pay entry points

Development Trends

1. Device lag is narrowing, but reimbursement lag remains critical: PMDA / MHLW support innovation and accelerated review, while reimbursement points and hospital adoption often determine real launch timing.
2. MAH structure is a commercial control point: Separating registration-only MAH from distributor can reduce lock-in; bundled structures may be faster initially but costly to change later.
3. Japanese domestic device companies are strong: Olympus, Terumo, Fujifilm, Sysmex and peers hold important specialty and service-network advantages.
4. Clinical evidence is judged through Japanese usability: CE / FDA data helps, but Japanese population, JIS standards, package insert quality, and PMDA query responses drive review efficiency.
5. Digital health, AI, robotics, and ageing-related devices are growing: Software / AI, cybersecurity, real-world performance, and reimbursement classification requirements are becoming more detailed.

Regulatory Authority

• Competent Authorities:
  • PMDA (Pharmaceuticals and Medical Devices Agency, 独立行政法人医薬品医療機器総合機構): Responsible for technical review and QMS assessment (operational executing body)
  • MHLW (Ministry of Health, Labour and Welfare, 厚生労働省): Responsible for issuing final marketing approval
• Official Portals: https://www.pmda.go.jp; English: https://www.pmda.go.jp/english/index.html
• Key Regulations:
  • Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices (PMD Act, Act No. 84 of 2013)
  • Ministerial Ordinance on QMS for Medical Devices (MHLW Ordinance No. 169, 2004)
  • Product-specific guidance documents (jointly issued by MHLW/PMDA)
  • General Principles of Safety and Performance for Medical Devices (2020, corresponding to EU MDR Annex I)

Device Classification System

Local Classification	Risk Level	EU/FDA Equivalent	Description
Class I (General Medical Devices)	Lowest risk	EU Class I / FDA Class I	No PMDA review required; manufacturer/MAH self-certifies conformity
Class II (Controlled Medical Devices — lower)	Low-moderate risk	EU Class IIa / FDA Class II	Ninsho (Certification) pathway; reviewed by registered certification bodies (登録認証機関)
Class II (Controlled Medical Devices — higher)	Moderate risk	EU Class IIb / FDA Class II	Shonin (Approval) pathway; PMDA/MHLW review
Class III (Specially Controlled Medical Devices)	High risk	EU Class III / FDA Class III	Shonin pathway; PMDA technical review + MHLW final approval
Class IV (Specifically Designated Specially Controlled Medical Devices)	Highest risk	EU Class III / FDA PMA	Shonin pathway; most stringent review standard; clinical data typically required

Note: Classification is determined by the MHLW Medical Device Classification List. Confirming product classification is the critical first step for any Japan market entry.

Registration Pathways

During the limited-time free period, sign in or register to view the complete medical device country report.